Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Valentis (VLTS) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (37)	1/9/2001 5:07:42 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 81

vlts is broadcasting from H&Q, so I assume it will be archived for a day or so. A good listen. Lots of info in the presentation. Review of gene medicines and so on, but there is unmistakable excitement about polymasc peg. It is specifically designed for biopharmceuticals like proteins, antibodies and so is in a sweet spot of current drug development efforts. Have successfully peg'd 20 straight proteins without loss of their effectiveness. "huge" number of oppys to do deals, high demand, schering's PEG is shining a light on other methods like polymasc, and there are undisclosed existing partnerships. $55m cash, $24m burn. W54